The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01A | Antiinfectives | |
| 4 | S01AE | Fluoroquinolones | |
| 5 | S01AE06 |
| Active Ingredient | Description | |
|---|---|---|
| Gatifloxacin |
Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZYMAR 0.3% w/v Ophthalmic solution | Health Products and Food Branch (CA) | MPI, CA: SPM | |
| ZYMAXID Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
